Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Benchmark Holdings plc (BHCCF)
Sheffield, GB
Benchmark Holdings plc is dedicated to empowering the food and agriculture sectors by furnishing specialized knowledge, services, and products. The company's operations are divided into three core divisions: Genetics, Advanced Nutrition, and Health. Within its Genetics arm, Benchmark provides cutting-edge breeding technologies and facilities for species such as sea bass/bream, salmon, shrimp, and tilapia, delivering genetically superior ova. The Advanced Nutrition division focuses on creating and supplying vital nutritional and health products specifically for the aquaculture industry. Meanwhile, the Health segment offers crucial medicinal solutions for the aquaculture market, including treatments like Ectosan Vet and CleanTreat for sea lice. Founded in 2000 and headquartered in Sheffield, United Kingdom, Benchmark Holdings plc maintains a broad international presence, conducting business in diverse regions including the UK, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, other European countries, and worldwide.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -53.70% | -53.70% | -56.46% | -56.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-46.7% Q1'25: -42.4% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-121.6% Q1'25: +6,766.7% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-14.5% Q1'25: +41.5% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-41.9% Q1'25: -14.7% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-13.9% Q1'25: -7.6% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.0% Q1'25: +0.2% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.57× Q1'25: 22.85× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 2 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
44.20M
est: 42.10M (+5.0%)
|
109.38M
est: 106.06M (+3.1%)
|
140.17M
est: 137.35M (+2.1%)
|
151.47M
est: 149.37M (+1.4%)
|
127.34M
est: 150.70M (-15.5%)
|
105.57M
est: 115.29M (-8.4%)
|
125.06M
est: 121.18M (+3.2%)
|
158.28M
est: 155.17M (+2.0%)
|
169.48M
est: 173.93M (-2.6%)
|
90.37M
est: 149.04M (-39.4%)
|
78.48M
est.
|
85.85M
82.57M – 89.13M
+9.4% YoY
|
91.75M
88.25M – 95.26M
+6.9% YoY
|
| EBITDA |
-6.96M
est: 5.37M (-229.5%)
|
-4.58M
est: 13.54M (-133.9%)
|
11.56M
est: 17.53M (-34.1%)
|
18.85M
est: 19.07M (-1.1%)
|
30.93M
est: 19.24M (+60.8%)
|
14.34M
est: 14.72M (-2.5%)
|
23.45M
est: 15.47M (+51.6%)
|
20.54M
est: 19.81M (+3.7%)
|
10.80M
est: 22.20M (-51.4%)
|
10.97M
est: 19.02M (-42.3%)
|
10.02M
est.
|
10.96M
10.54M – 11.38M
+9.4% YoY
|
11.71M
11.26M – 12.16M
+6.9% YoY
|
| EBIT |
-11.33M
est: -5.64M (-100.7%)
|
-21.19M
est: -14.21M (-49.1%)
|
-6.14M
est: -18.41M (+66.6%)
|
-5.99M
est: -20.02M (+70.1%)
|
-52.39M
est: -20.20M (-159.4%)
|
-14.20M
est: -15.45M (+8.1%)
|
-1.19M
est: -16.24M (+92.7%)
|
-4.68M
est: -20.79M (+77.5%)
|
-13.09M
est: -23.31M (+43.8%)
|
-37.88M
est: -19.97M (-89.7%)
|
-10.52M
est.
|
-11.50M
-11.94M – -11.06M
-9.4% YoY
|
-12.30M
-12.77M – -11.83M
-6.9% YoY
|
| Net Income |
-11.99M
est: -29.53M (+59.4%)
|
-18.34M
est: 6.10M (-400.8%)
|
-7.44M
est: 2.59M (-387.6%)
|
-5.01M
est: -5.59M (+10.4%)
|
-83.86M
est: -17.65M (-375.1%)
|
-32.92M
est: -28.70M (-14.7%)
|
-12.89M
est: -10.02M (-28.7%)
|
-32.09M
est: -14.96M (-114.5%)
|
-23.15M
est: -4.11M (-462.9%)
|
-39.46M
est: -1.52M (-2,492.5%)
|
34.14M
est.
|
7.62M
7.24M – 7.99M
-77.7% YoY
|
10.03M
9.53M – 10.53M
+31.7% YoY
|
| SGA |
—
est: 7.58M (-100.0%)
|
—
est: 19.10M (-100.0%)
|
452.0K
est: 24.73M (-98.2%)
|
—
est: 26.89M (-100.0%)
|
214.0K
est: 27.13M (-99.2%)
|
33.32M
est: 20.76M (+60.5%)
|
38.27M
est: 21.82M (+75.4%)
|
44.10M
est: 27.94M (+57.8%)
|
—
est: 31.31M (-100.0%)
|
—
est: 26.83M (-100.0%)
|
14.13M
est.
|
15.46M
14.87M – 16.05M
+9.4% YoY
|
16.52M
15.89M – 17.15M
+6.9% YoY
|
| EPS |
-0.06
est: -0.04 (-49.0%)
|
-0.04
est: 0.01 (-631.4%)
|
-0.01
est: 0.00 (-505.9%)
|
-0.01
est: -0.01 (-24.3%)
|
-0.15
est: -0.02 (-528.5%)
|
-0.05
est: -0.04 (-35.5%)
|
-0.02
est: -0.01 (-42.5%)
|
-0.05
est: -0.02 (-127.4%)
|
-0.02
est: -0.01 (-230.9%)
|
-0.05
est: 0.00 (-2,494.4%)
|
0.05
est.
|
0.01
0.01 – 0.01
-77.7% YoY
|
0.01
0.01 – 0.01
+31.7% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Roland James Bonney | Group Lead of Key Account Management | 364.3K | male |
| Ruth Layton | Co-Founder & Head of Benchmark Sustainability Science | 19.1K | female |
| David Babington | Managing Director of Improve International | — | male |
| Ivonne Maria Gloria Cantu | Secretary, Director of Investor Relations & Corpo Development and Head of Sustainability | — | female |
| Jonas Jónasson | Global Production Director for Salmon - Benchmark Genetics | — | — |
| Bob Long | Managing Director of Benchmark Vaccines Ltd | — | male |
| Patrick Waty | Chief Executive Officer | — | male |
| Pierre Hugo | Chief Financial Officer | — | male |
| Neil Robertson | Head of Operations | — | male |
| Corina Holmes | Group Head of People | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BHCCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
